Archive for March 21st, 2012

FDA Adcom votes against ridaforolimus. TRGT Phase 3 fail. PATH NDA update + CXM AEGR news

Mar 21, 2012 No Comments by

NuPathe Inc. (NASDAQ: PATH) gave an update noting that it intends to submit its New Drug Application for its migraine patch (NP101) during 1H 2012. Merck (NYSE: MRK) and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA), announced today that the FDA Oncologic Drugs Advisory Committee (ODAC) voted 13 to 1 against the use of ridaforolimus for patients with metastatic soft-tissue sarcoma or bone sarcoma […]

Daily News Read more